Futura Medical PLC
08 March 2004
Press Release 08 March 2004
Futura Medical Plc
Issue of Equity
Futura Medical plc ('Futura'), the AIM-quoted pharmaceutical and medical device
group that develops innovative products for the sexual healthcare market, is
pleased to announce that it has raised £1.75 million, after costs, by way of a
joint placing, between Williams de Broe Plc and Canaccord Capital (Europe)
Limited, of 2,200,000 ordinary shares at 82 pence per share, under its Section
95 authority. The money raised from this issue will enhance Futura's
negotiation opportunities with its potential distributors as well as finance new
development opportunities. The placing was undertaken in response to the
considerable interest shown in Futura by a variety of institutional investors
since the release of the preliminary results for the year-ended 31 December 2003
last week.
Application has been made for 2,200,000 ordinary shares to be admitted to
trading on the Alternative Investment Market of the London Stock Exchange. It
is expected that admission to trading and dealings in the new ordinary shares
will commence at 8.00am on 10th March 2004.
James Barder, Chief Executive of Futura Medical, said: 'There is always a risk
that small companies like Futura may be squeezed when negotiating commercial
distribution agreements if they are seen as being cash constrained. The
additional funding will strengthen our negotiating position as well as finance
other development opportunities that have started to come our way following
Futura's Introduction to AIM and increase in profile. We are delighted to be
able to welcome a number of institutional investors as new shareholders to the
Company, thereby further expanding our shareholder base.'
For further information:
Futura Medical plc
James Barder, Chief Executive Tel: +44 (0) 1483 845 670
mailto:james.barder@futuramedical.co.uk www.futuramedical.co.uk
Media enquiries:
Bankside
Peter Curtain / Alex Tweed Tel: +44 (0) 20 7444 4140
mailto:alexandra.tweed@bankside.com www.bankside.com
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.